AT368505B - Verfahren zur herstellung des neuen tetrahydroisoxazol(5,4-c)pyridin-3-ols und von dessen salzen - Google Patents

Verfahren zur herstellung des neuen tetrahydroisoxazol(5,4-c)pyridin-3-ols und von dessen salzen

Info

Publication number
AT368505B
AT368505B AT0448678A AT448678A AT368505B AT 368505 B AT368505 B AT 368505B AT 0448678 A AT0448678 A AT 0448678A AT 448678 A AT448678 A AT 448678A AT 368505 B AT368505 B AT 368505B
Authority
AT
Austria
Prior art keywords
tetrahydroisoxazole
ols
pyridin
salts
producing
Prior art date
Application number
AT0448678A
Other languages
English (en)
Other versions
ATA448678A (de
Inventor
Povl Krogsgaard-Larsen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of ATA448678A publication Critical patent/ATA448678A/de
Application granted granted Critical
Publication of AT368505B publication Critical patent/AT368505B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
AT0448678A 1977-06-20 1978-06-20 Verfahren zur herstellung des neuen tetrahydroisoxazol(5,4-c)pyridin-3-ols und von dessen salzen AT368505B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2574077 1977-06-20

Publications (2)

Publication Number Publication Date
ATA448678A ATA448678A (de) 1982-02-15
AT368505B true AT368505B (de) 1982-10-25

Family

ID=10232513

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0448678A AT368505B (de) 1977-06-20 1978-06-20 Verfahren zur herstellung des neuen tetrahydroisoxazol(5,4-c)pyridin-3-ols und von dessen salzen

Country Status (14)

Country Link
US (2) US4278676A (de)
EP (4) EP0000167A1 (de)
JP (2) JPS5436290A (de)
AT (1) AT368505B (de)
AU (2) AU3724478A (de)
CA (1) CA1107736A (de)
DK (2) DK270278A (de)
ES (2) ES470913A1 (de)
FI (2) FI64376C (de)
IE (1) IE47200B1 (de)
IT (2) IT7868449A0 (de)
NO (3) NO782128L (de)
NZ (1) NZ187615A (de)
ZA (2) ZA783493B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3145474A1 (de) * 1980-11-27 1982-09-02 Kefalas A/S, Koebenhavn-Valby 3-substituierte 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridinverbindungen, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3145473A1 (de) * 1980-11-27 1982-08-26 Kefalas A/S, Koebenhavn-Valby 2-substituierte 4,5,6,7-tetrahydroisoxazolo (5,4-c) pyridin-3-on-verbindungen, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
EP0083378A1 (de) * 1981-12-22 1983-07-13 Chugai Seiyaku Kabushiki Kaisha Tetrahydronicotinsäureamide, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
GB8314391D0 (en) * 1983-05-24 1983-06-29 Kefalas As Heterocyclic compounds
IT1228426B (it) * 1987-07-20 1991-06-17 Ausimont Spa Perossiacidi eterociclici
US4859666A (en) * 1988-07-06 1989-08-22 Bristol-Myers Company THAZ derivatives for enhancement of cerebral function
CN1043051C (zh) * 1994-07-22 1999-04-21 国际壳牌研究有限公司 制备氢化石蜡的方法
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
MXPA05013016A (es) 2003-06-25 2006-03-02 Lundbeck & Co As H Gaboxadol para el tratamiento de la depresion y otros trastornos afectivos.
AR045540A1 (es) * 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
PL1691811T3 (pl) * 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
US20050215521A1 (en) * 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
JP2007517040A (ja) * 2003-12-24 2007-06-28 セプレイコー インコーポレイテッド 睡眠の質を改善するためのメラトニン併用療法
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
CA2556870C (en) * 2004-02-18 2014-01-28 Timothy J. Barberich Dopamine-agonist combination therapy for improving sleep quality
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP2292222A1 (de) 2005-01-28 2011-03-09 H. Lundbeck A/S Polymorphe Formen eines GABAA-Agonisten
WO2006118897A1 (en) * 2005-04-29 2006-11-09 H.Lundbeck A/S Acid and base salt forms of gaboxadol
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258358A3 (de) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
EP2377530A3 (de) 2005-10-21 2012-06-20 Braincells, Inc. Modulation von Neurogenese durch PDE-Hemmung
EP1942879A1 (de) 2005-10-31 2008-07-16 Braincells, Inc. Gaba-rezeptor-vermittelte modulation von neurogenese
US20070203216A1 (en) * 2006-02-14 2007-08-30 Bjarke Ebert Method of treating inflammatory diseases
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100193652A1 (en) * 2009-02-02 2010-08-05 William Stajos Wall Display System And Method Of Providing The Same
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8784835B2 (en) * 2012-07-02 2014-07-22 Trent Austin Method for producing muscimol and/or reducing ibotenic acid from amanita tissue
CN104974175A (zh) * 2014-04-11 2015-10-14 天津药物研究院 一种氨甲基羟异恶唑类似物的制备方法
SI3372229T1 (sl) 2014-06-06 2021-09-30 Ovid Therapeutics, Inc. Postopki za povečanje tonične inhibicije in zdravljenje angelman sindroma
CN107428776B (zh) 2015-03-24 2020-10-23 H.隆德贝克有限公司 制造4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
BR112018000933A2 (pt) 2015-07-17 2018-09-04 Ovid Therapeutics Inc métodos de tratamento de um distúrbio de desenvolvimento
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
JP2019524816A (ja) 2016-08-11 2019-09-05 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． てんかん性障害の処置のための方法および組成物
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
MX2020001342A (es) 2017-08-04 2020-08-31 Ovid Therapeutics Inc Uso de gaboxadol en el tratamiento contra diabetes y afecciones relacionadas.
MX2021003302A (es) 2018-09-20 2021-05-13 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez.
WO2020106927A1 (en) 2018-11-21 2020-05-28 Certego Therapeutics Gaboxadol for reducing risk of suicide and rapid relief of depression
MX2021007224A (es) 2018-12-17 2021-09-23 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del trastorno del sue?o vigilia que no es de 24 horas.
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
CN114292224B (zh) * 2022-03-07 2022-05-20 中国农业科学院农产品加工研究所 一种大麻二酚-2-（n-乙酰基）哌啶酸酯及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2784190A (en) * 1952-03-28 1957-03-05 Upjohn Co Alkyl piperidinepropionates
CA762455A (en) * 1962-03-22 1967-07-04 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Pyrido-pyrimidines
US3381016A (en) * 1966-03-04 1968-04-30 Upjohn Co Isoxazolo[5, 4-b]pyridine derivatives and a method for their preparation
DE2221770A1 (de) * 1972-05-04 1973-11-15 Bayer Ag Verfahren zur herstellung von tetrahydropyridinen
DK62791A (da) * 1991-04-09 1992-11-09 Tulip Int As Fremgangsmaade til saltning af koed samt anlaeg til brug ved udoevelse af fremgangsmaaden

Also Published As

Publication number Publication date
EP0027279A1 (de) 1981-04-22
IT1159739B (it) 1987-03-04
IT7868450A0 (it) 1978-06-20
FI781955A7 (fi) 1978-12-21
ES470913A1 (es) 1979-02-01
JPS5436275A (en) 1979-03-16
EP0000167A1 (de) 1979-01-10
CA1107736A (en) 1981-08-25
ES470912A1 (es) 1979-02-01
ATA448678A (de) 1982-02-15
NO782128L (no) 1978-12-21
FI64376B (fi) 1983-07-29
ZA783492B (en) 1979-06-27
FI64376C (fi) 1983-11-10
AU521040B2 (en) 1982-03-11
AU3729878A (en) 1980-01-03
ZA783493B (en) 1979-06-27
US4278676A (en) 1981-07-14
NO152049B (no) 1985-04-15
EP0000338A3 (en) 1979-06-27
IT7868449A0 (it) 1978-06-20
IE47200B1 (en) 1984-01-11
AU3724478A (en) 1980-01-03
NO782127L (no) 1978-12-21
DK270278A (da) 1978-12-21
EP0000338B1 (de) 1981-11-25
DK270378A (da) 1978-12-21
FI781954A7 (fi) 1978-12-21
NO792839L (no) 1978-12-21
NZ187615A (en) 1981-12-15
NO152049C (no) 1985-07-24
JPS5436290A (en) 1979-03-16
EP0000338A2 (de) 1979-01-24
IE781234L (en) 1978-12-20
EP0028017A1 (de) 1981-05-06
US4301287A (en) 1981-11-17

Similar Documents

Publication Publication Date Title
AT368505B (de) Verfahren zur herstellung des neuen tetrahydroisoxazol(5,4-c)pyridin-3-ols und von dessen salzen
AT369750B (de) Verfahren zur herstellung des neuen 11-aza-4-0cladinosyl-6-0-desosaminyl-15-aethyl-7,13,14-
AT366374B (de) Verfahren zur herstellung von neuen n3substituierten 5,5-dimethylhydantoinen
AT347582B (de) Verfahren zur herstellung des neuen 4'- deoxydaunomycins
AT363491B (de) Verfahren zur herstellung von neuen 1,3,8trisubstituierten xanthinen und deren salzen
AT361487B (de) Verfahren zur herstellung von neuen pyrazolo(1, 5c)chinazolinen und ihren salzen
ATA750778A (de) Verfahren zur herstellung des neuen antibiotisc wirksamen deoxynarasinkomplexes
DD136832A5 (de) Verfahren zur herstellung von 1,2-dichloraethan
AT380883B (de) Verfahren zur herstellung von neuen 1-oxo-1h -thiazolo(3,2-a)pyrimidin-2-carboxamiden
AT359070B (de) Verfahren zur herstellung von neuen 2,4-diamino -5-benzylpyrimidinen und deren salzen
AT360524B (de) Verfahren zur herstellung von neuen 1,2- benzisothiazolen
AT352696B (de) Verfahren zur herstellung von cyclohexandion- (1,4)-tetramethyldiketal
AT352697B (de) Verfahren zur herstellung von neuen cyclohexen- (1)-dion-(3,6)-tetraalkyldiketalen
AT361925B (de) Verfahren zur herstellung des neuen n-6-chlor- nicothinoyl-d,1-homocysteinthiolactons und dessen salzen
DD132497A1 (de) Verfahren zur herstellung von neuen gona-4,9(10)-dienen
DD128359A5 (de) Verfahren zur herstellung von 5,6-dehydropenicillinen
AT373872B (de) Verfahren zur herstellung von 2,2-dialkyl-4-methyl-5,5-dialkyl-3-formyl-3-pyr olinen
ATA91780A (de) Verfahren zur herstellung des neuen 2-benzyl-3(3-dimethylaminopropylthio)-2h-indazols und von dessen salzen
DD132347A5 (de) Verfahren zur herstellung von 17-acetalen von 3-alkoxy-oestra-2,5(10)-dien-17-onen
ATA501779A (de) Verfahren zur herstellung des neuen 2,4,6-tris- -chlorsulfenyl-s-triazin
ATA42180A (de) Verfahren zur herstellung von neuen 2,4- -diamino-5-benzylpyrimidinen und deren salzen
ATA42280A (de) Verfahren zur herstellung von neuen 2,4- -diamino-5-benzylpyrimidinen und deren salzen
ATA707379A (de) Verfahren zur herstellung von neuen 1,1- -dithienyl-(3)-1-hydroxy-alkylhalogeniden
AT352719B (de) Verfahren zur herstellung des neuen 2,6,6- trimethyl-2-cyanmethyl-tetrahydropyrans
AT367069B (de) Verfahren zur herstellung des 3beta-hydroxy-14, 15beta-oxido-14beta-burfa-4,20,22-trienolid, 3beta-(alpha-l-rhamnopyranosids)

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee